Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
302.00K | 314.00K | 1.77M | 2.96M | 1.05M | Gross Profit |
302.00K | -1.01M | 1.02M | 2.34M | -27.25M | EBIT |
-299.04M | -254.45M | -134.30M | -79.73M | -110.38M | EBITDA |
-266.36M | -234.56M | -128.63M | -78.79M | -109.67M | Net Income Common Stockholders |
-269.95M | -237.73M | -125.44M | -79.42M | -110.98M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
717.58M | 477.37M | 424.55M | 196.97M | 127.64M | Total Assets |
742.40M | 490.42M | 435.09M | 203.71M | 131.25M | Total Debt |
21.09M | 21.05M | 5.26M | 520.00K | 455.00K | Net Debt |
-78.50M | -81.78M | -150.32M | -41.78M | -45.44M | Total Liabilities |
70.76M | 48.40M | 40.03M | 15.99M | 11.22M | Stockholders Equity |
671.64M | 442.02M | 395.06M | 187.72M | 120.04M |
Cash Flow | Free Cash Flow | |||
-232.83M | -185.07M | -94.64M | -54.92M | -29.82M | Operating Cash Flow |
-232.32M | -184.17M | -93.84M | -54.58M | -29.78M | Investing Cash Flow |
-228.65M | -94.25M | -115.13M | -74.29M | -50.48M | Financing Cash Flow |
457.74M | 225.67M | 322.24M | 125.28M | 101.31M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $1.12B | 29.94 | 11.23% | ― | 29.20% | ― | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
51 Neutral | $1.13B | ― | -49.41% | ― | 4.86% | 10.13% | |
48 Neutral | $909.52M | ― | -93.70% | ― | ― | -25.83% | |
47 Neutral | $938.68M | ― | -105.50% | ― | -7.06% | -57.17% | |
42 Neutral | $885.32M | ― | -45.35% | ― | 22264.23% | 39.09% | |
39 Underperform | $637.81M | ― | -51.85% | ― | 11070.12% | 32.07% |
On May 20, 2025, Viridian Therapeutics announced positive long-term durability data from its THRIVE phase 3 clinical trial for veligrotug, an anti-IGF-1R antibody for thyroid eye disease (TED). The trial showed that 70% of patients maintained their response at week 52, with no changes in safety profile. Veligrotug has received Breakthrough Therapy Designation, and the company plans a Biologics License Application submission in the second half of 2025, with a commercial launch anticipated in 2026.
The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
On April 7, 2025, Viridian Therapeutics announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer brings over 25 years of experience in commercialization for rare diseases, having previously served as Chief Commercial Officer at BioMarin Pharmaceutical. His expertise is expected to bolster Viridian’s commercial strategy as the company advances its pipeline, including veligrotug for thyroid eye disease. Additionally, Viridian announced inducement grants of stock options to new employees, aligning with its growth and recruitment strategies.
On March 3, 2025, Viridian Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $300 million in common stock to support clinical development and commercialization efforts. This new agreement replaces a prior sale agreement from September 2022, which was terminated after selling $115.2 million in stock, with no costs associated with its early termination.